Activation of the PX1/IL-1β axis in CD41+/CD62P+ platelets enhances pancreatic ductal adenocarcinoma invasion and metastasis

Hao Li,Wang Jiang,Shirong Zhang,Huaxiang Xu,Pengcheng Li,Tianjiao Li,Wei Jin,Dexian Quan,Yiming Yang,Longyun Ye,Shuaishuai Xu,Xianjun Yu,Liang Liu

DOI: https://doi.org/10.21203/rs.3.rs-307202/v1

2021-01-01

Abstract:Abstract The pro-tumor mechanisms of platelets in pancreatic ductal adenocarcinoma (PDAC) are poorly understood. We showed that the count of the CD41+/CD62P + platelets subtype was significantly elevated in stage III/IV patients. An increased level of CD41+/CD62P + platelets could serve as an independent risk factor for stage I/II patients after surgery. Furthermore, we found significantly higher PX1 expression in CD41+/CD62P + platelets than in CD41+/CD62P- platelets in PDAC patients. Mechanistically, PX1 was able to enhance IL-1β secretion in platelets via phosphorylating p38 MAPK and consequently promoted PDAC invasion and metastasis. Finally, we constructed a novel compound named PC63435 by the ligation of carbenoxolone (PX1 inhibitor) and PSGL-1 (CD62P ligand). PC63435 specifically bound to CD41+/CD62P + platelets and blocked the PX1/IL-1β pathway, which suppressed PDAC tumor invasion and metastasis. Our findings revealed that the activation of PX1 in CD41+/CD62P + platelets enhanced PDAC cell malignancy and that may be a potent target for PDAC therapy.